Objective To retrospectively evaluate clinical efficacy and safety of Lianhua Qingwen Granules（连花清瘟颗粒） combined with western medicine conventional therapy in the treatment of coronavirus disease 2019（COVID-19） suspected cases. Methods Medical records of 101 COVID-19 suspected patients admitted in CR & WISCO General Hospital Affiliated to Wuhan University of Science and Technology from January 1 to January 27

2020 were retrospectively analyzed. Among them

63 patients received conventional therapy in combination with Lianhua Qingwen Granules were taken as treatment group

and 38 patients received only conventional therapy were in the control group. Clinical data 10 days after the treatment were collected. A comparison between the 2 groups was performed in terms of disappearance rates of cardinal symptoms（fever

cough and weakness）

duration of fever and disappearance rates of other individual symptoms and signs. Results The disappearance rates of fever

cough and weakness in the treatment group were 86.7%

55.6% and 82.5%

respectively

which were higher than those in the control group（67.7%

30.6% and 58.6%; P<0.05）. In the treatment group

the median duration of fever was 6 days in patients with fever disappeared

and it was 7 days in the control group. There was no statistically significant difference between groups（P=0.171）. The disappearance rates of short breath and moist crackles（68.2% and 56.0%） were higher than those in the control group（20.0% and 20.0%

P<0.05）. There were 4 cases of aggravation in the treatment group（6.4%）

while 6 cases in the control group（15.8%）

without statistically significant difference（P>0.05）. There were no obvious adverse reactions in the treatment group. Conclusion Lianhua Qingwen Granules combined with western medicine conventional therapy can significantly relieve symptoms like fever

cough

weakness and short breath in COVID-19 suspected cases with good safety.